A comprehensive view of ImmunoGen Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

AbbVie Inc. Reinforces Industry Presence with Strategic ImmunoGen Acquisition, Expanding Oncology Reach in Solid Tumors
Published: February 13, 2024 by Industry Intelligence Inc.
AbbVie completes acquisition of ImmunoGen, adding the flagship antibody-drug conjugate ELAHERE for ovarian cancer treatment to its portfolio; the deal increases AbbVie's oncology portfolio
Published: February 12, 2024 by AbbVie Inc.
AbbVie to acquire ImmunoGen for US$10.1B, including its flagship cancer therapy Elahere mirvetuximab soravtansine-gynx, expanding its solid tumor portfolio; Elahere is a first-in-class antibody-drug conjugate approved for platinum-resistant ovarian cancer
Published: November 30, 2023 by AbbVie Inc.

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count